Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR, Matsumoto S, Lee HJ, Honda H, Kwon OK, Ishikawa T, Lee KH, Nabeshima K, Kong SH, Shimokawa T, Yook JH, Doki Y, Im SA, Hirota S, Hahn S, Nishida T, Kang YK. Kurokawa Y, et al. Among authors: im sa. Br J Cancer. 2017 Jun 27;117(1):25-32. doi: 10.1038/bjc.2017.144. Epub 2017 May 23. Br J Cancer. 2017. PMID: 28535156 Free PMC article. Clinical Trial.
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: im yh. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.
Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6.
Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY. Han SW, et al. Among authors: im sa. Cancer Sci. 2010 Mar;101(3):793-9. doi: 10.1111/j.1349-7006.2009.01447.x. Epub 2009 Nov 23. Cancer Sci. 2010. PMID: 20047592 Free article. Clinical Trial.
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.
Kim JS, Baek JY, Park SR, Choi IS, Kim SI, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Kim JS, et al. Among authors: im sa. Cancer Res Treat. 2004 Dec;36(6):372-6. doi: 10.4143/crt.2004.36.6.372. Epub 2004 Dec 31. Cancer Res Treat. 2004. PMID: 20368831 Free PMC article.
660 results